DefEYE, Inc.

DefEYE, Inc. , based in the US, specializes in biologic solutions aimed at improving the treatment and management of ocular surface diseases through innovative products designed for healthcare professionals. DefEYE, Inc. focuses on providing biologic solutions for ocular health.

The company has undergone strategic shifts to enhance its offerings and is headquartered in the United States. Recent funding rounds have solidified its position in the market. In November 2025, DefEYE, Inc. raised an undisclosed amount of seed funding from new investor ExSight Ventures, specializes in a portfolio of innovative decellularized biologic solutions designed to enhance the treatment and management of ocular surface diseases and surgical interventions.

Their flagship product, BIOVANCE® 3L Ocular, utilizes a unique triple-layer design that facilitates improved healing for various eye conditions, including persistent epithelial defects and pterygium surgery. These products are intended for use by healthcare professionals in the field of ophthalmology, targeting both surgical procedures and ongoing management of ocular diseases. DefEYE™ products are primarily marketed to hospitals, outpatient surgical centers, and ophthalmic practices across the United States, reflecting a commitment to advancing ocular care through evidence-based solutions. The company's emphasis on room-temperature storage and a variety of shapes and sizes for its products ensures accessibility and versatility in clinical settings.

DefEYE™, Inc. generates revenue through direct sales of its biologic solutions to healthcare providers and institutions. The company employs a business-to-business model, catering to hospitals and surgical centers that incorporate its products into their treatment protocols. Transactions are structured around product orders, with practitioners purchasing BIOVANCE® 3L Ocular and related offerings as needed to address specific patient cases.

This transactional framework allows for tailored solutions based on the unique needs of individual patients, supporting the company's mission to improve ocular health. The firm’s focus on delivering high-quality products that address complex ocular conditions positions it as a key player in the ophthalmic market, contributing to its revenue stream through strategic partnerships and repeat business from satisfied clients. In November 2025, DefEYE, Inc. raised an undisclosed amount of seed funding from new investor ExSight Ventures.

The company will utilize the funding to accelerate the commercialization and expansion of its decellularized placental tissue solutions for eye care. Future initiatives include the launch of new products specifically designed for ocular treatments, with plans to enter new markets in North America and Europe by 2026. The strategic expansion aims to broaden their reach and enhance their product offerings in the global ophthalmic market.